Phenoxypropazine

Phenoxypropazine

Phenoxypropazine
Systematic (IUPAC) name
(1-methyl-2-phenoxy-ethyl)hydrazine
Clinical data
Legal status
  • Prescription only
Routes Oral
Identifiers
CAS number
ATC code None
PubChem
ChemSpider
UNII
ChEMBL
Chemical data
Formula C9H14N2O 
Mol. mass 166.22 g/mol

Phenoxypropazine (trade name Drazine) is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine family. It was introduced as an antidepressant in 1961, but was subsequently withdrawn in 1966 due to hepatotoxicity concerns.[1][2][3][4][5]

See also

References

  1. ^ LEAHY MR, ROSE JT, PLOWMAN R (April 1963). "A preliminary study of phenoxypropazine in the treatment of depression". The American Journal of Psychiatry 119: 986–7.  
  2. ^ IMLAH NW (May 1963). "Preliminary report on phenoxypropazine". The American Journal of Psychiatry 119: 1091–2.  
  3. ^ ROSE JT, LEAHY MR, PLOWMAN R (October 1963). "A comparison of phenoxypropazine and amitriptyline in depression". The American Journal of Psychiatry 120: 393–5.  
  4. ^ ROSE JT (March 1964). "Phenoxypropazine and chlordiazepoxide in depression". The American Journal of Psychiatry 120: 899–900.  
  5. ^ MCWHINNEY IR, MORRELL DC (January 1965). "Treatment of mild endogenous depression with a monoamine oxidase inhibitor: a controlled trial in general practice". The Journal of the College of General Practitioners 9: 95–9.